Revvity revised 2025 profit forecast downward citing China policy impact on diagnostics demand (reuters.com)

• Revvity lowered 2025 adjusted EPS forecast to $4.80-$4.85 from $4.95-$5.05.
• Weak demand in China due to government procurement policy changes.
• Q2 revenue $689M, down 3%, slightly above estimates.
• Shares fell 5% in premarket trading.

"Revvity lowered its 2025 adjusted profit forecast due to weaker demand in China from government procurement policy changes. The company now expects adjusted earnings per share between $4.80 and $4.85, down from $4.95 to $5.05. Shares fell 5% in premarket trading."